title: Mutual interaction of special phytoestrogenic compounds, their synthetic carboxy-derivatives and the less-calcemic vitamin D analog activities in human derived female cultured osteoblasts.
abstract: Cultured female-derived human bone cells (hObs) responded by different parameters to different phytoestrogenic and vitamin D compounds. Pre- and post-menopausal hObs express ERα and ERβ mRNA with higher abundance of ERα. Pre-treatment with the less-calcemic vitamin D analog JKF 1624F(2)-2 (JKF) upregulated responsiveness to estrogens via modulation of ERs expression. These estrogenic compounds induce the expression and activity of 25 hydroxy-vitamin D(3)-1α hydroxylase (1OHase). We now analyzed the effects of carboxy-genistein (cG), carboxy-biocainin A (cBA) and carboxy-daidzein (cD), of BA, D or G and of licorice derived compounds glabridin (Glb) and glabrene (Gla) and estradiol-17β (E(2)) on DNA synthesis, creatine kinase specific activity (CK), intracellular and membranal E(2) binding and their modulations by JKF in hObs. We also analyzed modulation by phytoestrogenic compounds of 1OHase mRNA expression and activity. We showed that: (1) all compounds stimulated DNA synthesis and CK. (2) JKF and all estrogenic compounds modulated ERα and ERβ mRNA expression. (3) Pre-treatment with JKF increased DNA synthesis and CK responses only to E(2), D, G and Gla. (4) JKF increased the intracellular competitive binding only of E(2), D and G. (5) JKF abolished the membranal binding of all protein-bound estrogens. (6) JKF and all estrogenic compounds except the protein-bound ones up-regulated 1OHase expression and activity. In conclusion phytoestrogens and their analogs increase DNA synthesis and CK, and lead to increased production of 1,25(OH)(2)D(3) in hObs, while pre-treatment with JKF modulates the effect of estrogenic compounds via regulation of ERs mRNA expression in a yet unclear mechanism.
authors.affiliation: Institute of Endocrinology, Metabolism and Hypertension and Bone Diseases Unit, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel. dalias@tasmc.health.gov.il
authors.forename: D
authors.initials: D
authors.lastname: Somjen
authors.forename: S
authors.initials: S
authors.lastname: Katzburg
authors.forename: O
authors.initials: O
authors.lastname: Sharon
authors.forename: G H
authors.initials: GH
authors.lastname: Posner
authors.forename: N
authors.initials: N
authors.lastname: Jaccard
authors.forename: D
authors.initials: D
authors.lastname: Hendel
authors.forename: S
authors.initials: S
authors.lastname: Tamir
authors.forename: J
authors.initials: J
authors.lastname: Vaya
mesh_terms: D001483:Base Sequence; D002478:Cells, Cultured; D017931:DNA Primers; D005260:Female; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects*; D048789:Phytoestrogens / Q000494:pharmacology*; D060888:Real-Time Polymerase Chain Reaction; D011960:Receptors, Estrogen / Q000187:drug effects; D014807:Vitamin D / Q000031:analogs & derivatives / Q000494:pharmacology*
chemical_list: D017931:DNA Primers; D048789:Phytoestrogens; D011960:Receptors, Estrogen; D014807:Vitamin D